Oligonucleotide Synthesis - Global Strategic Business Report

The global market for Oligonucleotide Synthesis was estimated at US$8.3 Billion in 2024 and is projected to reach US$19.9 Billion by 2030, growing at a CAGR of 15.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oligonucleotide Synthesis market.

Global Oligonucleotide Synthesis Market - Key Trends & Drivers Summarized

What Is Oligonucleotide Synthesis and Why Is It Gaining Global Attention?

Oligonucleotide synthesis refers to the chemical process used to create short sequences of nucleotides, the building blocks of DNA and RNA. These synthetic oligonucleotides are essential for a variety of applications, ranging from diagnostics and therapeutics to genetic research and biotechnology. The ability to custom-build DNA or RNA strands through synthetic processes has revolutionized molecular biology, allowing researchers to design specific sequences for targeted genetic interventions, gene editing, and pharmaceutical development. Oligonucleotides play a crucial role in modern biotechnology, supporting applications such as PCR (polymerase chain reaction), DNA sequencing, gene synthesis, and antisense therapeutics. As a key enabling technology, oligonucleotide synthesis underpins breakthroughs in genomics, personalized medicine, and drug discovery, making it indispensable to life sciences and healthcare.

How Is Technology Shaping the Evolution of Oligonucleotide Synthesis?

Technological advancements have been pivotal in the evolution of oligonucleotide synthesis, driving higher precision, scalability, and efficiency in the production process. Innovations such as automated synthesizers and improved solid-phase synthesis methods have significantly accelerated the rate at which oligonucleotides can be manufactured, making it easier to meet the growing demands of pharmaceutical and biotechnology industries. Additionally, recent developments in high-throughput synthesis technology allow for the parallel production of large libraries of oligonucleotides, enabling faster research in fields like gene editing and CRISPR technology. The advent of next-generation sequencing (NGS) technologies has further heightened the need for high-quality oligonucleotides, as precise and custom-designed sequences are critical for NGS workflows. Companies are investing heavily in enhancing the purity, length, and sequence fidelity of synthesized oligonucleotides, pushing the boundaries of what can be achieved in genetic research and molecular diagnostics.

Why Are Oligonucleotides Essential in Therapeutics and Diagnostics?

The rising interest in oligonucleotides for therapeutic and diagnostic applications has been a significant driver for the market. In therapeutics, oligonucleotides are used to create antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, all of which can modulate gene expression or protein function. These therapies are being explored for the treatment of genetic disorders, cancers, and rare diseases, offering a new class of drugs that are highly targeted and personalized. Additionally, in diagnostics, synthetic oligonucleotides are critical in the development of assays for detecting genetic mutations, pathogens, and biomarkers. The COVID-19 pandemic, for example, highlighted the critical role of oligonucleotides in the development of diagnostic tests such as PCR assays, which rely on short, custom-designed DNA primers. The rapid expansion of gene therapy, immunotherapy, and precision medicine has created a robust demand for custom oligonucleotide synthesis services, further cementing the role of this technology in advancing healthcare.

What Are the Major Drivers Fueling the Growth of the Oligonucleotide Synthesis Market?

The growth in the oligonucleotide synthesis market is driven by several factors, each contributing uniquely to its expansion. One of the primary drivers is the increasing demand for synthetic oligonucleotides in therapeutic development, particularly for genetic therapies aimed at treating rare and complex diseases. The rapid rise of CRISPR and gene-editing technologies has also fueled the need for high-quality oligonucleotides that can be used as guide RNAs and other components essential for gene manipulation. The growing field of personalized medicine, where treatments are tailored to the genetic profile of individual patients, is further driving the demand for custom oligonucleotide synthesis. Additionally, the widespread adoption of next-generation sequencing and molecular diagnostics has significantly expanded the market for oligonucleotides used in diagnostic assays and research. With advancements in manufacturing technologies, including automation and high-throughput synthesis, companies can now produce oligonucleotides more efficiently and at lower costs, making them accessible to a broader range of researchers and pharmaceutical companies. The continued investment in biotechnology, coupled with an increasing focus on genomics, is expected to sustain robust growth in this market for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Oligonucleotide Synthesis market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Product (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Equipment); Application (Therapeutics, Diagnostics, Research); End-Use (Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies, Other End-Uses)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Oligonucleotide-Based Drugs segment, which is expected to reach US$8.6 Billion by 2030 with a CAGR of a 17.3%. The Synthesized Oligonucleotides segment is also set to grow at 15.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.2 Billion in 2024, and China, forecasted to grow at an impressive 21.2% CAGR to reach $4.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Oligonucleotide Synthesis Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oligonucleotide Synthesis Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Oligonucleotide Synthesis Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as ATDBio Ltd., Bio-Synthesis Inc., Eurogentec, GE Healthcare Life Sciences, GeneDesign, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 41 companies featured in this Oligonucleotide Synthesis market report include:

• ATDBio Ltd.
• Bio-Synthesis Inc.
• Eurogentec
• GE Healthcare Life Sciences
• GeneDesign, Inc.
• GenScript Biotech Corporation
• Integrated DNA Technologies (IDT), Inc.
• LGC Biosearch Technologies
• Merck KgaA
• Nitto Denko Avecia Inc.
• Thermo Fisher Scientific, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.